Cabazitaxel

Get a Price/Quote

Product Details:

Formulations Type Injectables
Formulations Form Liquid
Gender/Age Group Adult
Click to view more

Ask A Question Send Inquiry

Product Specifications

Formulations Form Liquid
Gender/Age Group Adult
Formulations Type Injectables

Trade Information

Payment Terms Cash on Delivery (COD), Cash Advance (CA), Delivery Point (DP), Western Union
Main Export Market(s) Asia, Australia, Central America, North America, South America, Eastern Europe, Western Europe, Middle East, Africa
Main Domestic Market All India

Product Description

Cabazitaxel (previously XRP-6258, trade name Jevtana) is a semi-synthetic derivative of a natural taxoid.^[1] It was developed by Sanofi-Aventis and was approved by the U.S. FDA for the treatment of hormone-refractory prostate cancer on June 17, 2010. It is a microtubule inhibitor, and the fourth taxane to be approved as a cancer therapy.^[2]^{[unreliable source?]}

Cabazitaxel in combination with prednisone is a treatment option for hormone-refractory prostate cancer following docetaxel-based treatment.